Travere Therapeutics' Share-based Compensation rose 40.40% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 18.90%. This contributed to the annual value of $36.9 million for FY2024, which is 16.57% down from last year.
Latest data reveals that Travere Therapeutics reported Share-based Compensation of $11.3 million as of Q3 2025, which was up 5.77% from $10.6 million recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Share-based Compensation peaked at $13.5 million during Q1 2023, and registered a low of $7.0 million during Q3 2021.
Over the past 3 years, Travere Therapeutics' median Share-based Compensation value was $10.6 million (recorded in 2025), while the average stood at $10.4 million.
Its Share-based Compensation has fluctuated over the past 5 years, first soared by 73.20% in 2022, then decreased by 29.14% in 2024.
Quarterly analysis of 5 years shows Travere Therapeutics' Share-based Compensation stood at $7.4 million in 2021, then rose by 26.04% to $9.3 million in 2022, then decreased by 12.40% to $8.1 million in 2023, then climbed by 13.14% to $9.2 million in 2024, then soared by 40.40% to $11.3 million in 2025.
Its Share-based Compensation was $11.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $11.5 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value